Phase I Trial of Bortezomib (NSC 681239) and Flavopiridol (NSC 649890) in Patients with Recurrent or Refractory Indolent B-Cell Neoplasms Grant, S., Sullivan, D., Roodman, D., Stuart, R. K., Perkins, E., Kolla, S., Rarnakrishnan, V., Wright, J., Colevas, A., Tombes, M. B., Roberts, J. D. AMER SOC HEMATOLOGY. 2008: 558

View details for Web of Science ID 000262104701794